Invest4 publishers2 min readPublished
Onsemi's $5.7 billion cash bid for Synaptics lands 16% above the market price
Onsemi will pay $123 a share in cash, about $5.7 billion, for Synaptics after a rival bid, replacing a June stock deal valued near $7 billion. The cash price sits 16% above Synaptics' Thursday close, so holders gain on the market even as the headline total shrinks.
The Investor · Invest desk
What happened
- Synaptics' board reviewed the amended terms with its financial and legal advisers and unanimously found them in shareholders' best interests.
- Synaptics shares rose 14% on Friday, the day after the revision, and onsemi's gained about 6%.
- Onsemi now expects the purchase to add to its non-GAAP earnings per share immediately after closing.
- The Federal Trade Commission has already approved the deal, and reviews in other jurisdictions are still underway.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- cost Onsemi owners now fund the full price with cash and Morgan Stanley debt, so the day-one accretion claim depends on interest costs staying below what Synaptics earns.
- constraint A counterbidder would have to top a cash offer that already has FTC clearance and committed debt behind it, with no financing condition to test.
- decision Synaptics shareholders now vote on a fixed cash amount, so their choice turns on whether the rival returns, with onsemi's share price out of the calculation.
A competing bid normally pushes a price up, so a revision that takes about $1.3 billion off the headline needs explaining [1][2]. The June agreement paid Synaptics holders in onsemi stock [3], and onsemi's shares now sit nearly 40% below their June record [5]. Investopedia, in a report carried by Yahoo Finance, said the move to cash may ease doubts that built up after that drop [20]. The sources do not give the exchange ratio, so the old offer's value on Thursday cannot be rebuilt from them. Synaptics' own share price is a cleaner mark. A $123 price at a 16% premium [4] puts Thursday's close near $106 [2]. If the two headline values are on the same basis, the June terms implied about $151 a share [3].
On that evidence, Synaptics' board took certainty and a premium together, measured against a stock offer the market had already marked down. "By transitioning to an all-cash structure, we are providing value certainty at a meaningful premium as compared to current value," Rahul Patel, Synaptics' chief executive, said [18]. The counter-case is the upside his holders hand back. Onsemi stock is up 57% this year even after its slide [19], and a stock with that range could have carried a share-based offer back toward its June value.
Onsemi's chief executive, Hassane El-Khoury, presented the switch as a saving for his own holders. "The all-cash transaction delivers higher value to our shareholders through lower total cost consideration," he said [17]. Bank of America analysts wrote that the terms "could be received more favorably by investors as it removes the dilution overhang while preserving the strategic rationale" [16]. No new onsemi shares go to Synaptics investors [15].
The synergy target did not change. Onsemi still expects at least $200 million a year in run-rate synergies [8], about 3.5% of the $5.7 billion price [4][1]. Revenue synergies and moving part of Synaptics' production in-house come on top, and they start contributing only after the first 18 months post-close [9]. Against a close expected by mid-2027 [11], that puts the insourcing money at around the end of 2028 at the earliest [5]. For the first year and a half, onsemi's case rests on the cost target and the financing.
A counterbid is the clearest way this turns out differently, and the market is pricing it as unlikely. A 14% gain on Friday [13] takes a roughly $106 stock to about $121, some $2 under the cash price on rounded figures [6]. If Synaptics trades above $123 before its shareholders vote [11], the market expects a higher offer and this view is wrong.
What to watch
- The size and interest rate of onsemi's Morgan Stanley-backed borrowing, set against its promise of immediate non-GAAP EPS accretion.
- Whether the reviews outside the US clear in time for the mid-2027 closing target.
- The date and result of the Synaptics shareholder vote, and any disclosure of who made the competing proposal and on what terms.